CL2014003329A1 - Un metodo para el tratamiento del sobrepeso o la obesidad, en un sujeto que corre un riesgo mayor de sufrir un resultado cardiovascular adverso, que comprende identificar a un sujeto obeso o con sobrepeso y administrar naltrexona de liberacion sostenida o una de sus sales y bupropion de liberacion sostenida o una de sus sales. - Google Patents

Un metodo para el tratamiento del sobrepeso o la obesidad, en un sujeto que corre un riesgo mayor de sufrir un resultado cardiovascular adverso, que comprende identificar a un sujeto obeso o con sobrepeso y administrar naltrexona de liberacion sostenida o una de sus sales y bupropion de liberacion sostenida o una de sus sales.

Info

Publication number
CL2014003329A1
CL2014003329A1 CL2014003329A CL2014003329A CL2014003329A1 CL 2014003329 A1 CL2014003329 A1 CL 2014003329A1 CL 2014003329 A CL2014003329 A CL 2014003329A CL 2014003329 A CL2014003329 A CL 2014003329A CL 2014003329 A1 CL2014003329 A1 CL 2014003329A1
Authority
CL
Chile
Prior art keywords
salts
overweight
sustained release
subject
bupropion
Prior art date
Application number
CL2014003329A
Other languages
English (en)
Spanish (es)
Inventor
Preston Klassen
Kristin Taylor
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003329(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of CL2014003329A1 publication Critical patent/CL2014003329A1/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01G—WEIGHING
    • G01G19/00—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups
    • G01G19/40—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight
    • G01G19/413—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight using electromechanical or electronic computing means
    • G01G19/414—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight using electromechanical or electronic computing means using electronic computing means only
    • G01G19/4146—Weighing apparatus or methods adapted for special purposes not provided for in the preceding groups with provisions for indicating, recording, or computing price or other quantities dependent on the weight using electromechanical or electronic computing means using electronic computing means only for controlling caloric intake, e.g. diet control
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • G09B19/0092—Nutrition
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B5/00—Electrically-operated educational appliances
    • G09B5/06—Electrically-operated educational appliances with both visual and audible presentation of the material to be studied
    • G09B5/065—Combinations of audio and video presentations, e.g. videotapes, videodiscs, television systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Mathematical Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Nutrition Science (AREA)
  • Multimedia (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014003329A 2012-06-06 2014-12-05 Un metodo para el tratamiento del sobrepeso o la obesidad, en un sujeto que corre un riesgo mayor de sufrir un resultado cardiovascular adverso, que comprende identificar a un sujeto obeso o con sobrepeso y administrar naltrexona de liberacion sostenida o una de sus sales y bupropion de liberacion sostenida o una de sus sales. CL2014003329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261656451P 2012-06-06 2012-06-06

Publications (1)

Publication Number Publication Date
CL2014003329A1 true CL2014003329A1 (es) 2015-04-06

Family

ID=49712605

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003329A CL2014003329A1 (es) 2012-06-06 2014-12-05 Un metodo para el tratamiento del sobrepeso o la obesidad, en un sujeto que corre un riesgo mayor de sufrir un resultado cardiovascular adverso, que comprende identificar a un sujeto obeso o con sobrepeso y administrar naltrexona de liberacion sostenida o una de sus sales y bupropion de liberacion sostenida o una de sus sales.

Country Status (38)

Country Link
US (4) US9633575B2 (enExample)
EP (4) EP4629257A3 (enExample)
JP (4) JP2015518897A (enExample)
KR (6) KR20150016405A (enExample)
CN (2) CN110893181A (enExample)
AR (2) AR093694A1 (enExample)
AU (2) AU2013271622B2 (enExample)
BR (1) BR112014030282A2 (enExample)
CA (1) CA2875056C (enExample)
CL (1) CL2014003329A1 (enExample)
CO (1) CO7240377A2 (enExample)
CY (2) CY1123183T1 (enExample)
DK (3) DK3730132T3 (enExample)
EA (1) EA201492175A1 (enExample)
EC (1) ECSP15000223A (enExample)
ES (3) ES2802048T3 (enExample)
FI (1) FI4104824T3 (enExample)
GT (1) GT201400278A (enExample)
HK (1) HK1209057A1 (enExample)
HR (1) HRP20250931T1 (enExample)
HU (3) HUE072188T2 (enExample)
IL (3) IL300868A (enExample)
IN (1) IN2015DN00042A (enExample)
JO (1) JOP20130346B1 (enExample)
LT (3) LT4104824T (enExample)
MA (1) MA37714A1 (enExample)
MX (4) MX382311B (enExample)
NI (1) NI201400144A (enExample)
PE (1) PE20150358A1 (enExample)
PL (3) PL2858640T3 (enExample)
PT (3) PT3730132T (enExample)
RS (3) RS60682B1 (enExample)
SI (1) SI4104824T1 (enExample)
SM (1) SMT202500290T1 (enExample)
TN (1) TN2014000508A1 (enExample)
TW (1) TW201904575A (enExample)
WO (1) WO2013184837A1 (enExample)
ZA (1) ZA201409218B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
PE20150358A1 (es) 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
US10332053B2 (en) * 2013-02-13 2019-06-25 Tutsho, Llc Food data access and delivery system
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US10638786B2 (en) * 2017-08-16 2020-05-05 Zolighter, LLC Methods of reducing visceral fat and related compositions
US11007121B2 (en) * 2018-02-15 2021-05-18 Robin ARORA Systems, methods and apparatus for substance dependence cessation management
RU2706385C1 (ru) * 2019-01-09 2019-11-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения больных метаболическим синдромом
WO2021101694A1 (en) * 2019-11-18 2021-05-27 Mandometer Ab Eating disorder diagnosis
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (254)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3942641A (en) 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US4089855A (en) 1976-04-23 1978-05-16 Cornell Research Foundation, Inc. Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
US4218433A (en) 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4217353A (en) 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
IL58649A (en) 1978-11-10 1982-04-30 Beecham Group Ltd Pharmaceutical dispensing container
ZA824382B (en) 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
JPS58134019A (ja) 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
DE3381877D1 (de) 1982-03-16 1990-10-18 Univ Rockefeller Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4895845A (en) 1986-09-15 1990-01-23 Seed John C Method of assisting weight loss
NL8800823A (nl) 1987-04-10 1988-11-01 Sandoz Ag Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
ES2058272T3 (es) 1987-05-04 1994-11-01 Lilly Co Eli Fluoxetina util para el tratamiento de la diabetes.
US5000886A (en) 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
EP0483152A4 (en) 1989-05-09 1992-12-02 Whitby Research Incorporated A method of reducing body weight and food intake using a dopamine d2 receptor agonist
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
DE69005992T2 (de) 1989-12-06 1994-05-05 Akzo Nv Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen.
FR2657350B1 (fr) 1990-01-19 1992-05-15 Centre Nat Rech Scient Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
DE4136215A1 (de) 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
IT1265240B1 (it) 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
EP0782445B1 (en) 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
CA2228610C (en) 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
JPH11505547A (ja) 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
EP0795327A1 (en) 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
ATE344668T1 (de) 1996-05-07 2006-11-15 Pliva Istrazivanje I Razvoj D Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6087386A (en) 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
IL127715A (en) 1996-06-28 2004-07-25 Ortho Mcneil Pharm Inc Anticonvulsant sulfamate derivatives useful in treating obesity
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
DE69828289T2 (de) 1997-08-11 2005-06-02 Alza Corp., Mountain View Dosierungsform für verzögerte Freisetzung eines Wirkstoffs
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
KR20010030860A (ko) 1997-10-03 2001-04-16 캐리 메디컬 코퍼레이션 니코틴 리셉터 길항제, 및 항-진정제 또는 항-불안 약물을함유하는 니코틴 중독치료용 조성물
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP1040830B1 (en) 1997-12-26 2005-06-08 Dainippon Pharmaceutical Co., Ltd. Remedy for neurodegenerative diseases
KR100568063B1 (ko) 1998-01-21 2006-04-07 글락소 그룹 리미티드 제약상 활성인 모르폴리놀
EP1051167A1 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (-) -bupropion
US6048322A (en) 1998-04-15 2000-04-11 Kushida; Clete Morphometric measurement tool
US6153223A (en) 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US20030144174A1 (en) 1998-12-09 2003-07-31 Miles B. Brennan Methods for identifying compounds useful for the regulation of body weight and associated conditions
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6210716B1 (en) 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030035840A1 (en) 2001-02-08 2003-02-20 Boyong Li Controlled release oral dosage form
US6589553B2 (en) 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6387956B1 (en) 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
DE60037818D1 (de) 1999-04-01 2008-03-06 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
CZ20013607A3 (cs) 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
ES2291215T3 (es) 1999-06-14 2008-03-01 Vivus, Inc. Terapia de combinacion para producir perdida de peso y tratar la obesidad.
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US20040115134A1 (en) 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
DE60019473T2 (de) 1999-07-01 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
US6071918A (en) 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
JP2003509349A (ja) 1999-09-15 2003-03-11 エラン ファーマシューティカルズ，インコーポレイテッド ヘテロアリールメタンスルホンアミドを使用するニューロパシー性疼痛を処置するための方法。
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US6410736B1 (en) 1999-11-29 2002-06-25 Pfizer Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
AU7750100A (en) 1999-10-13 2001-04-23 Glaxo Group Limited Method for the treatment of obesity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
WO2001052851A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
CA2397726A1 (en) 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US20020090615A1 (en) 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN101703777B (zh) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
EP1263438B1 (en) 2000-03-15 2006-05-17 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US8030294B2 (en) 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
AU5066101A (en) 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
AU2001250646A1 (en) 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US6306436B1 (en) 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
JP2004505043A (ja) 2000-08-02 2004-02-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド うつ病の治療で用いるに有用な抗痙攣性誘導体
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
PT1333887E (pt) 2000-10-30 2006-10-31 Ortho Mcneil Pharm Inc Metodo de tratamento de desordens musculares
RU2197250C2 (ru) 2000-10-30 2003-01-27 Соколовский Сергей Ростиславович Способ лечения наркоманий
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CA2445528A1 (en) 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
EP1262196A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US6960357B2 (en) 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
PT1411900E (pt) 2001-06-01 2010-10-11 Pozen Inc Composições farmacêuticas para a entrega coordenada de aines
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
US6462237B1 (en) 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
EP1414418A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030087896A1 (en) 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030044462A1 (en) 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
ITFI20010230A1 (it) 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
EP1455751A1 (en) 2001-12-20 2004-09-15 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20040029941A1 (en) 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US20050215552A1 (en) 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR20110043664A (ko) 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
BR0309969A (pt) 2002-05-17 2005-04-26 Merck Patent Gmbh Uso de compostos que são eficazes como moduladores de receptores seletivos de opiáceos
US20040005368A1 (en) 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US6972291B2 (en) 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US20040258757A1 (en) 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
EP1534074A4 (en) 2002-07-18 2008-01-09 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF FATIBILITY
US7086532B2 (en) 2003-07-16 2006-08-08 Allergan, Inc. Titration/compliance pack with increasing doses
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US7273884B2 (en) 2002-09-13 2007-09-25 Eisai, Inc. Method of treating tremors
AU2003268380A1 (en) 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040092504A1 (en) 2002-11-12 2004-05-13 Anuthep Benja-Athon Definitive medications for treating fibromyalgia
US6893660B2 (en) 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040122033A1 (en) 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
AU2003296672A1 (en) 2002-12-13 2004-07-09 Cilag Ag Controlled release preparations comprising tramadol and topiramate
CA2414500A1 (en) 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
AU2003303631B2 (en) 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004071423A2 (en) 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
US20040158194A1 (en) 2003-02-06 2004-08-12 Wolff Andy And Beiski Ben Z. Oral devices and methods for controlled drug release
WO2004078113A2 (en) 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
EP1772147A2 (en) 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
WO2004087175A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
WO2004091593A2 (en) 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
BRPI0410271A (pt) 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
BRPI0419067A (pt) 2003-05-16 2007-12-11 Pfizer Prod Inc método para aumento da cognição utilizando ziprasidona
EP1635773A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. (a New Jersey corp.) Combination therapy for the treatment of hypertension
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
EP1635813A4 (en) 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1663179A1 (en) 2003-07-21 2006-06-07 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
BRPI0318456B8 (pt) 2003-08-08 2021-05-25 Biovail Laboratories Int Srl tablete com liberação modificada
CA2534924A1 (en) 2003-08-08 2005-02-24 Elan Pharma International Ltd. Novel metaxalone compositions
US20050043704A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043773A1 (en) 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043705A1 (en) 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050112211A1 (en) 2003-08-21 2005-05-26 Eric Gervais Micronutrient supplement
HRP20100368T1 (hr) 2003-09-25 2010-08-31 Euro-Celtique S.A. Farmaceutske kombinacije hidrokodona i naltreksona
US20050112198A1 (en) 2003-10-27 2005-05-26 Challapalli Prasad V. Bupropion formulation for sustained delivery
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050147664A1 (en) 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005049043A1 (en) 2003-11-18 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising metformin and anticonvulsant agents
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
EP1776089A2 (en) 2003-12-31 2007-04-25 Actavis Group hf Donepezil formulations
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US20060160750A1 (en) 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1727538A2 (en) 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
SE0400378D0 (sv) 2004-02-17 2004-02-17 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
MXPA06009991A (es) 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20060100205A1 (en) 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
BRPI0510593A (pt) 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
US20050250838A1 (en) 2004-05-04 2005-11-10 Challapalli Prasad V Formulation for sustained delivery
CN101001619A (zh) 2004-08-03 2007-07-18 奥雷西根治疗公司 影响体重减轻的安非他酮和第二化合物的组合物
DK1781265T3 (da) 2004-08-25 2010-08-02 Essentialis Inc Farmaceutiske formuleringer af kalium ATP-kanal-åbnere og anvendelser deraf
US20060069086A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1804785A2 (en) 2004-10-27 2007-07-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
JP2008519078A (ja) 2004-11-04 2008-06-05 ニューロゲン コーポレイション Ｃｂ１拮抗薬としてのアリールアルキル尿素類
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
JP2006232675A (ja) 2005-02-22 2006-09-07 Kowa Co 複合型口腔内溶解用固形製剤
AU2006236387A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl CB1 antagonists
US20060246131A1 (en) 2005-04-28 2006-11-02 Cottlingham Elizabeth M Use of metformin to counteract weight gain associated with psychotropic medications
JP2008542378A (ja) 2005-05-31 2008-11-27 オレキシジェン・セラピューティクス・インコーポレーテッド 精神病性障害を管理する方法および組成物
WO2007012064A2 (en) 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
BRPI0613911A2 (pt) 2005-07-27 2011-02-22 Orexigen Therapeutics Inc composições para afetar a perda de peso
PT3524261T (pt) 2005-08-19 2024-01-12 Amylin Pharmaceuticals Llc Exendina para o tratamento da diabetes e redução do peso corporal
WO2007047351A2 (en) 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
AR058239A1 (es) 2005-11-28 2008-01-23 Orexigen Therapeutics Inc Metodos para tratar trastornos de ansiedad
ES2383330T3 (es) 2005-11-28 2012-06-20 Orexigen Therapeutics, Inc. Formulación de liberación sostenida de zonisamida
WO2007084290A2 (en) 2006-01-12 2007-07-26 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
JP5478245B2 (ja) * 2006-06-05 2014-04-23 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソンの徐放型配合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20150029762A (ko) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
WO2008011150A1 (en) 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US8682445B2 (en) 2006-07-28 2014-03-25 Cyberonics, Inc. Patient management system for treating depression using an implantable medical device
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
GB2447949B (en) 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
RU2342195C1 (ru) 2007-04-18 2008-12-27 Институт проблем комплексного освоения недр РАН Устройство для механоактивации сульфидсодержащих минеральных продуктов
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US8846053B2 (en) 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP6196041B2 (ja) * 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
EP2642988A1 (en) 2010-11-26 2013-10-02 Ramot at Tel-Aviv University Ltd Method and composition for weight-gain management
PL2646031T3 (pl) 2010-12-03 2017-08-31 Orexigen Therapeutics, Inc. Wzrost biodostępności leku w terapii naltreksonem
WO2012075453A1 (en) 2010-12-03 2012-06-07 Orexigen Therapeutics, Inc. Methods for reducing binge or compulsive eating
PE20150358A1 (es) * 2012-06-06 2015-04-06 Orexigen Therapeutics Inc Metodos para el tratamiento del sobrepeso y de la obesidad
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Also Published As

Publication number Publication date
PE20150358A1 (es) 2015-04-06
SMT202500290T1 (it) 2025-09-12
EP4629257A2 (en) 2025-10-08
EA201492175A1 (ru) 2015-10-30
PT2858640T (pt) 2020-06-30
ES2802048T3 (es) 2021-01-15
KR20200035501A (ko) 2020-04-03
HUE059651T2 (hu) 2022-12-28
ES3037824T3 (en) 2025-10-07
EP4629257A3 (en) 2025-12-10
MA37714A1 (fr) 2017-12-29
PT3730132T (pt) 2022-08-16
EP4104824A1 (en) 2022-12-21
US20220208327A1 (en) 2022-06-30
ES2924024T3 (es) 2022-10-04
MX392254B (es) 2025-03-21
DK3730132T3 (da) 2022-08-08
SI4104824T1 (sl) 2025-09-30
MX369990B (es) 2019-11-27
NI201400144A (es) 2015-07-15
KR20230010811A (ko) 2023-01-19
JP2015518897A (ja) 2015-07-06
GT201400278A (es) 2017-08-01
RS67076B1 (sr) 2025-08-29
KR20150016405A (ko) 2015-02-11
IL282128A (en) 2021-05-31
MX2014014822A (es) 2015-05-11
JP2021080274A (ja) 2021-05-27
EP3730132B1 (en) 2022-05-04
JOP20130346B1 (ar) 2022-03-14
US9633575B2 (en) 2017-04-25
MX2022005401A (es) 2022-05-25
TW201904575A (zh) 2019-02-01
CA2875056A1 (en) 2013-12-12
US20170221380A1 (en) 2017-08-03
PT4104824T (pt) 2025-08-12
CY1125490T1 (el) 2025-05-09
HK1209057A1 (zh) 2016-03-24
JP2018158945A (ja) 2018-10-11
DK2858640T3 (da) 2020-06-29
IL235939A0 (en) 2015-01-29
US11139056B2 (en) 2021-10-05
EP3730132A1 (en) 2020-10-28
PL4104824T3 (pl) 2025-11-12
MX2019008217A (es) 2019-09-13
KR20240090733A (ko) 2024-06-21
LT3730132T (lt) 2022-08-25
ECSP15000223A (es) 2015-09-30
AU2018203271A1 (en) 2018-05-31
FI4104824T3 (fi) 2025-08-06
EP2858640A4 (en) 2016-01-20
CN110893181A (zh) 2020-03-20
JP2023086769A (ja) 2023-06-22
CO7240377A2 (es) 2015-04-17
PL3730132T3 (pl) 2022-10-10
US20150154883A1 (en) 2015-06-04
IN2015DN00042A (enExample) 2015-05-22
AU2013271622B2 (en) 2018-03-01
PL2858640T3 (pl) 2020-10-05
AU2013271622A1 (en) 2015-01-22
LT4104824T (lt) 2025-08-25
US20200098285A1 (en) 2020-03-26
ZA201409218B (en) 2024-05-30
TN2014000508A1 (en) 2016-03-30
DK4104824T3 (da) 2025-08-18
MX382311B (es) 2025-03-13
MX2019011209A (es) 2019-11-01
HUE049859T2 (hu) 2020-10-28
CA2875056C (en) 2024-03-26
EP2858640B1 (en) 2020-03-25
AR125234A2 (es) 2023-06-28
US10403170B2 (en) 2019-09-03
EP4104824B1 (en) 2025-05-21
AR093694A1 (es) 2015-06-17
LT2858640T (lt) 2020-08-10
RS63569B1 (sr) 2022-10-31
BR112014030282A2 (pt) 2017-06-27
HRP20250931T1 (hr) 2025-09-26
RS60682B1 (sr) 2020-09-30
CY1123183T1 (el) 2021-10-29
HUE072188T2 (hu) 2025-10-28
KR20210012056A (ko) 2021-02-02
IL300868A (en) 2023-04-01
CN104470512A (zh) 2015-03-25
KR20220042241A (ko) 2022-04-04
WO2013184837A1 (en) 2013-12-12
EP2858640A1 (en) 2015-04-15
JP6878360B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
CL2014003329A1 (es) Un metodo para el tratamiento del sobrepeso o la obesidad, en un sujeto que corre un riesgo mayor de sufrir un resultado cardiovascular adverso, que comprende identificar a un sujeto obeso o con sobrepeso y administrar naltrexona de liberacion sostenida o una de sus sales y bupropion de liberacion sostenida o una de sus sales.
Van Kippersluis et al. Wealth and health behavior: Testing the concept of a health cost
GT201600168A (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti dll3) y medicamentos para usarse en el tratamiento contra melanoma.
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
MX2016011761A (es) Dispositivo funcional medico con un asiento de la valvula de una valvula de retencion remanente.
CL2014000297A1 (es) Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos .
CL2014001370A1 (es) Un cartucho de toner para un dispositivo de formacion de imagenes, que comprende un alojamiento, una primera y segunda pata, una primera y una segunda guia de ala situada en una primera y segunda superficie lateral del alojamiento, un primer y segundo tope, y una par de proyecciones redondeadas.
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
EP3360591C0 (en) ACTIVATION MECHANISM FOR DRUG ADMINISTRATION DEVICE AND DRUG ADMINISTRATION DEVICE
BR112016022997A2 (pt) Elevador com um dispositivo de frenagem, e dispositivo de frenagem
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
AR097395A1 (es) Inhalador
LT3151853T (lt) Glutamo rūgšties dekarboksilazė (gad), skirta panaudoti autoimuninės ligos gydyme
BR112016010091A2 (pt) dispositivo de diagnóstico para a dermatologia com oct inserido e dermatoscopia de epiluminescência.
HUE058354T2 (hu) Hidrofil bevonattal rendelkezõ higiénikus orvosi eszközök és eljárások azok kialakítására
BR112017013580A2 (pt) combinações de inibidor de btk e regime de dosagem.
DK3188599T3 (da) Medicinske behandlinger baseret på anamorelin
EP3233162B1 (en) DRUG DELIVERY DEVICE HAVING A DOSING MEMBER AND COMBINED TRIGGER
LT3094616T (lt) Medžiagos, kurioje yra glicerilo tribenzoato, naudojimas gydant neurodegeneracinius sutrikimus
MX351228B (es) Metodos de diagnostico y tratamiento utilizando una genoteca de ligandos.
BR112016029238A2 (pt) método e aparelhos para fornecer uma solução para o tratamento de sangue.
FR3018193B1 (fr) Comprime vaginal muco-adhesif a liberation prolongee
CL2014000799A1 (es) Un metodo para el tratamiento de un paciente que ha sufrido un accidente cerebrovascular que comprende administrar aminopiridina o una de sus sales
ES1126055Y (es) Envase para medicamentos, productos dietéticos y productos similares.
BR112015004827A2 (pt) dispositivo de facilitação de transação financeira, métodos para facilitar e para processar uma transação financeira, e, instalação de processamento de transação financeira.